ICMR study reveals that Plasma Therapy isn’t beneficial in reducing COVID-19 deaths

A multi-centric study funded by the Indian Council of Medical Research (ICMR) has found that the use of convalescent plasma therapy in COVID-19 patients does not help in reducing mortality or progression to severe coronavirus infection. The study has been reviewed and approved by the National Task Force for COVID-19, a committee formed by the ICMR to respond to the pandemic.  

Between April 22 to July 14, the ‘open-label parallel-arm phase II multicentre randomized controlled trial’ (PLACID Trial) was conducted across 39 public and private hospitals across India to investigate the effectiveness of convalescent plasma (CP) for the treatment of coronavirus disease, said the top medical body. 

A total of 464 participants (moderately ill COVID-19 patients admitted to hospitals) were enrolled for the study that has not yet been peer-reviewed and has appeared on a preprint server medRxiv.  

Photo Credit : https://en.wikipedia.org/wiki/File:Indian_Council_of_Medical_Research_Logo.svg

Comments are closed, but trackbacks and pingbacks are open.